17 Murphy B R, Hall S L, Kulkarni A B, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res, 1994, 32: 13-36？？
[2]
18 Friedewald W T, Forsyth B R, Smith C B, et al. Low-temperature-grown RS virus in adult volunteers. JAMA, 1968, 204: 690-694
[3]
19 Belshe R B, Hissom F K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol, 1982, 10: 235-242？？
[4]
20 Belshe R B, Van Voris L P, Mufson M A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis, 1982, 145: 311-319
[5]
21 Wright P F, Karron R A, Belshe R B, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis, 2000, 182: 1331-1342？？
[6]
22 Schickli J H, Dubovsky F, Tang R S. Challenges in developing a pediatric RSV vaccine. Hum Vaccines, 2009, 5: 582-591
24 Crowe J E Jr, Collins P L, Chanock R M, et al. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. In: Levine M M W G, Kaper J B, Cobon G S, eds. New Generation Vaccines. New York: Marcel Dekker, 1997. 711-725
[9]
25 Chanock R M, Murphy B M. Past efforts to develop safe and effective RSV vaccines. In: Meignier B M B, Ogra P, eds. Animal Models of Respiratory Syncytial Virus Infections. Lyon: Merieux Foundation Publication, 1991. 35-42
[10]
26 Crowe J E Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine, 1995, 13: 415-421？？
[11]
27 Piazza F M, Johnson S A, Darnell M E, et al. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J Virol, 1993, 67: 1503-1510
[12]
28 Buchholz U J, Granzow H, Schuldt K, et al. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol, 2000, 74: 1187-1199？？
[13]
29 Whitehead S S, Firestone C Y, Collins P L, et al. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology, 1998, 247: 232-239？？
[14]
30 Whitehead S S, Juhasz K, Firestone C Y, et al. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol, 1998, 72: 4467-4471
[15]
31 Crowe J E Jr, Bui P T, London W T, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine, 1994, 12: 691-699？？
[16]
32 Crowe J E Jr, Bui P T, Davis A R, et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine, 1994, 12: 783-790？？
[17]
33 Crowe J E Jr, Bui P T, Siber G R, et al. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine, 1995, 13: 847-855？？
[18]
34 Karron R A, Wright P F, Crowe J E Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis, 1997, 176: 1428-1436？？
[19]
35 Whitehead S S, Firestone C Y, Karron R A, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol, 1999, 73: 871-877
[20]
36 Connors M, Crowe J E Jr, Firestone C Y, et al. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology, 1995, 208: 478-484？？
[21]
37 Firestone C Y, Whitehead S S, Collins P L, et al. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology, 1996, 225: 419-422？？
[22]
38 Crowe J E Jr, Firestone C Y, Whitehead S S, et al. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes, 1996, 13: 269-273？？
[23]
39 Karron R A, Wright P F, Belshe R B, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis, 2005, 191: 1093-1104？？
[24]
40 Juhasz K, Whitehead S S, Bui P T, et al. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol, 1997, 71: 5814-5819
[25]
41 Collins P L, Murphy B R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. PATS, 2005, 2: 166-173
[26]
43 Karron R A, Buonagurio D A, Georgiu A F, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA, 1997, 94: 13961-13966？？
[27]
44 Jin H, Zhou H, Cheng X, et al. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology, 2000, 273: 210-218
[28]
45 Whitehead S S, Bukreyev A, Teng M N, et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol, 1999, 73: 3438-3442
[29]
46 Bukreyev A, Whitehead S S, Murphy B R, et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol , 1997, 71: 8973-8982
[30]
47 Spann K M, Tran K C, Chi B, et al. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages
[31]
[corrected]. J Virol, 2004, 78: 4363-4369？？
[32]
48 Schlender J, Bossert B, Buchholz U, et al. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J Virol, 2000, 74: 8234-8242？？
[33]
49 Ramaswamy M, Shi L, Varga S M, et al. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology, 2006, 344: 328-339？？
[34]
50 Lo M S, Brazas R M, Holtzman M J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol, 2005, 79: 9315-9319？？
[35]
51 Bermingham A, Collins P L. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci USA, 1999, 96: 11259-11264？？
[36]
52 Jin H, Cheng X, Zhou H Z, et al. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J Virol, 2000, 74: 74-82？？
[37]
53 Teng M N, Whitehead S S, Bermingham A, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol, 2000, 74: 9317-9321？？
[38]
54 Wright P F, Karron R A, Madhi S A, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis, 2006, 193: 573-581？？
[39]
55 Wright P F, Karron R A, Belshe R B, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine, 2007, 25: 7372-7378？？
[40]
56 Krempl C, Murphy B R, Collins P L. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol, 2002, 76: 11931-11942？？
[41]
57 Widjojoatmodjo M N, Boes J, van Bers M, et al. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. J Virol, 2010, 7: 114？？
[42]
58 Nolan S M, Surman S R, Amaro-Carambot E, et al. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine, 2005, 23: 4765-4774？？
[43]
59 McAuliffe J M, Surman S R, Newman J T, et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol, 2004, 78: 2029-2036？？
[44]
60 Whitehead S S, Hill M G, Firestone C Y, et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol, 1999, 73: 9773-9780
[45]
61 Jin H, Clarke D, Zhou H Z, et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology, 1998, 251: 206-214？？
[46]
62 Collins P L, Murphy B R. Vaccines against human respiratory syncytial virus. In: Cane P, ed. Respiratory Syncytial Virus. Amsterdam: Elsevier, 2007. 233-277
[47]
63 Elango N, Prince G A, Murphy B R, et al. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci USA, 1986, 83: 1906-1910？？
[48]
64 Ball L A, Young K K, Anderson K, et al. Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci USA, 1986, 83: 246-250？？
[49]
65 de Waal L, Wyatt L S, Yuksel S, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine, 2004, 22: 923-926？？
[50]
66 Gutekunst R R, White R J, Edmondson W P, et al. Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol, 1967, 86: 341-349
[51]
67 Hsu K H, Lubeck M D, Bhat B M, et al. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine, 1994, 12: 607-612？？
[52]
42 Juhasz K, Whitehead S S, Boulanger C A, et al. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine, 1999, 17: 1416-1424？？
[53]
1 Fleming D M, Elliot A J. Respiratory syncytial virus: a sleeping giant? Eur Respir J, 2007, 30: 1029-1031
[54]
2 Karron R A. Respiratory Syncytial Virus Vaccine. In: Plotkin S A, Orenstein W A, Offit P A, eds. Vaccines, 5th ed. Philadelphia: Saunders, Elsevier, 2008. 1283-1293
[55]
3 Power U F. Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward. J Clin Virol, 2008, 41: 38-44？？
[56]
4 Englund J. In search of a vaccine for respiratory syncytial virus: the saga continues. J Infect Dis, 2005, 191: 1036-1039？？
[57]
5 Zeng R, Qi X, Gong W, et al. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine, 2007, 25: 7422-7428？？
[58]
6 Fu Y, He J, Zheng X, et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun, 2009, 381: 528-532？？
[59]
7 Fu Y H, He J S, Wang X B, et al. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Bioph Res Co, 2010, 395: 87-92？？
[60]
8 Xie C, He J S, Zhang M, et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther, 2007, 18: 746-752？？
[61]
9 Ghildyal R, Ho A, Jans D A. Central role of the respiratory syncytial virus matrix protein in infection. FEMS Microbiol Rev, 2006, 30: 692-705？？
[62]
10 Brandenburg A H, Neijens H J, Osterhaus A D. Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. Vaccine, 2001, 19: 2769-2782？？
[63]
11 Kumar M, Behera A K, Lockey R F, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther, 2002, 13: 1415-1425？？
[64]
12 Kapikian A Z, Mitchell R H, Chanock R M, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol, 1969, 89: 405-421
[65]
13 Kim H W, Canchola J G, Brandt C D, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol, 1969, 89: 422-434
[66]
14 Polack F P, Teng M N, Collins P L, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. JEM, 2002, 196: 859-865？？
[67]
15 Connors M, Giese N A, Kulkarni A B, et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol, 1994, 68: 5321- 5325
[68]
16 Schmidt A, Bartlett E, Schaap-Nutt A, et al. Vaccines against respiratory syncytial virus and parainfluenza viruses. In: Levine M M, Dougan G, Good M F, eds. New Generation Vaccines, 4th ed. New York: Informa Healthcare, 2009. 620-632
[69]
68 Hsu K H, Lubeck M D, Davis A R, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis, 1992, 166: 769-775
[70]
69 Collins P L, Prince G A, Camargo E, et al. Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins. In: Brown F, Chanock R M, Ginsberg H S, eds. Vaccines 90: Modern Approaches to New Vaccines Including Prevention of AIDS. New York: Cold Spring Harbor Laboratory Press, 1990. 79-84
[71]
70 Xiang Z Q, Yang Y, Wilson J M, et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology, 1996, 219: 220-227？？
[72]
71 Randrianarison-Jewtoukoff V, Perricaudet M. Recombinant adenoviruses as vaccines. Biologicals, 1995, 23: 145-157？？
[73]
72 Fu Y, He J, Zheng X, et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. BBRC, 2009, 381: 528-532
[74]
73 Kohlmann R, Schwannecke S, Tippler B, et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol, 2009, 83: 12601-12610？？
[75]
74 Yu J R, Kim S, Lee J B, et al. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol, 2008, 82: 2350-2357？？
[76]
75 Kim S, Jang J E, Yu J R, et al. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine, 2010, 28: 3801-3808？？
[77]
76 Weaver E A, Nehete P N, Buchl S S, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One, 2009, 4: e5059？？
[78]
77 Fu Y H, He J S, Zheng X X, et al. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. BBRC, 2010, 391: 857-861
[79]
78 Schmidt A C, McAuliffe J M, Murphy B R, et al. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol, 2001, 75: 4594-4603？？
[80]
79 Schmidt A C, Wenzke D R, McAuliffe J M, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol, 2002, 76: 1089-1099？？
[81]
80 Gomez N M, Walker R, Spaete R R, et al. Phase I study of a candidate live attenuated vaccine against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) in healthy adults. In: IDSA Meeting. Toronto, 2006, 183
[82]
81 Tang R S, MacPhail M, Schickli J H, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol, 2004, 78: 11198-11207？？
[83]
82 Pennathur S, Haller A A, MacPhail M, et al. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. J Gen Virol, 2003, 84: 3253-3261
[84]
83 Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol, 2006, 80: 1130-1139？？
[85]
84 Slobod K S, Shenep J L, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine, 2004, 22: 3182-3186？？
[86]
85 Takimoto T, Hurwitz J L, Coleclough C, et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol, 2004, 78: 6043-6047？？
[87]
86 Zhan X, Hurwitz J L, Krishnamurthy S, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine, 2007, 25: 8782-8793
